Clinical and cytogenetic variability on twelve Fanconi anemia families and its relationship with complementation group assignment;Variabilidad clínica y citogenética en doce familias mexicanas con anemia de Fanconi y su relación con el grupo de complementación al que pertenecen

Revista de Investigacion Clinica

Volumn 51, Issue 5, 1999, Pages 273-283

  Esmer Sánchez, María Del Carmen ^a   Carnevale Cantoni, Alessandra ^b   Molina Álvarez, Bertha ^a   Cruz Alcívar, Roberto ^a   Sánchez Sandoval, Silvia ^a   Gómez Laguna, Laura ^a   Frías Vázquez, Sara ^a  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b INP ^*

Author keywords

Complementation groups; Fanconi anemia; Genetic heterogeneity; Somatic mosaicism

Indexed keywords

ARTICLE; CHROMOSOME ABERRATION; FANCONI ANEMIA; FEMALE; GENETIC VARIABILITY; GENETICS; HUMAN; MALE; MEXICO;

CHROMOSOME ABERRATIONS; FANCONI ANEMIA; FEMALE; HUMANS; MALE; MEXICO; VARIATION (GENETICS);

EID: 0012832388     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Gordon EC, Rutherford TR. Fanconi anaemia-constitutional, familial aplastic anaemia. Bailleres Clin Haematol 1989; 2: 139-51.
2. Alter BP. Fanconi's anaemia and its variability. BJ Haematol 1993; 85: 9-14.
3. Joenje H, Mathew C, Gluckman E. Fanconi anaemia research: Current status and prospects. Eur J Cancer 1995; 31: 268-72.
4. Wegner RD, Henrichs Y, Joenje H, Schroeder-Kurth T. Fanconi anemia complementation group E: Clinical and cytogenetic data of the first patient. Clin Genet 1996; 50: 479-82.
5. Heim R, Lench N, Swiff M. Heterozygous manifestations in four autosomal recessive human cancer-prone syndromes: Ataxia telangiectasia, xeroderma pigmentosum, Fanconi anemia, and Bloom syndrome. Mutat Res 1992; 284: 25-36.
6. Frías S, Carnevale A, Del Castillo V. Utilidad de la prueba de exposición de linfocitos a mitomicina C en el diagnóstico de anemia de Fanconi. Rev Invest Clin 1984; 36: 219-21.
7. Carnevale A, Frias S. Efecto de la cocultivación y la adición de plasma normal sobre la respuesta a la mitomicina C de los linfocitos de anemia de Fanconi. Rev Invest Clin 1985; 37: 31-4.
8. Schroeder TM, Anschutz F, Knopp A. Spontaneous chromosome aberrations in familial panmyelopathy. Hum Genet 1964; 1: 194-9.
9. Sasaki MS, Tonomura A. A high susceptibility of Fanconi's anemia to chromosome breakage by DNA crosslinking agents. Cancer 1973; 33: 1829-36.
10. Auerbach AD, Wolman SR. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature 1976; 261: 494-6.
11. Frias S, Molina B, Carnevale A. Sinergismo bromodesoxiuridina-mitomicina C en la producción de aberraciones cromosómicas en anemia de Fanconi. Rev Invest Clin 1989; 41: 31-5.
12. Frias S, Mendoza S, Molina B, Carnevale A. Effect of mitomycin C and bromodeoxyuridine on Fanconi anemia lymphocytes. Ann Genet 1991; 34(2): 104-7.
13. Frias S, Molina B, Gómez L, Carnevale A. Efecto de la adición de medios condicionados sobre la respuesta de los linfocitos de anemia de Fanconi a la mitomicina C. Rev Invest Clin 1992; 44: 519-24.
14. Auerbach AD. Fanconi anemia diagnosis and the diepoxibutane (DEB) test. Exp Hematol 1993; 21: 731-6.
15. Papadopoulo D, Averbeck D, Moustacchi E. The fate of 8-methoxy-psoralen-photoinduced DNA interstrand cross-links in Fanconi's anemia cells of defined complementation groups. Mutat Res 1987; 184: 271-7.
16. Arwert F, Kwee L. Chromosomal breakage in response to cross-linking agents in the diagnosis of Fanconi anemia. In: Schroeder TM, Auerbach A and Obe G (eds). Fanconi anemia, clinical cytogenetic and experimental aspects. Berlin, Heidelberg: Springer-Verlag, 1989: 83-92.
17. Kwee ML, Poll EHA, van de Kamp JJP, Koning H, Eriksson AW, Joenje H. Unusual response to bifunctional alkylating agents in a case of Fanconi anaemia. Hum Genet 1983; 64: 384-7.
18. D'Andrea AD. Fanconi anaemia forges a novel pathway. Nature Genet 1996; 14: 240-2.
19. Auerbach AD, Korse RE, Ghosh R, Venkatraj VS, Zhang M, Chiorazzi N. Complementation studies in Fanconi anemia. In: Schroeder-Kurt TM, Auerbach AD, Obe G (eds). Fanconi anemia, clinical, cytogenetic and experimental aspects. Berlin, Heidelberg: Springer Verlag, 1989: 213-25.
20. Duckworth-Rysiecki G, Cornish K, Clarke C, Buchwald M. Identification of two complementation groups in Fanconi anemia. Somat Cell Mol Genet 1985; 11: 35-41.
21. Strathdee CA, Duncan AMV, Buchwald M. Evidence for at least four Fanconi anaemia genes including FACC on chromosome 9. Nature Genet 1992; 1: 196-8.
22. Joenje H, Lo Ten Foe JR, Oostra AB, van Berkel CGM, Rooimans MA, Schroeder-Kurt T et al. Classification of Fanconi anemia patients by complementation analysis: Evidence for a fifth genetic subtype. Blood 1995; 86 (12): 2156-60.
23. Joenje H, Lo Ten Foe JR, Oostra AB, Van Berkel CGM, di Summa F, Pronk JC. Fanconi anaemia in Europe. In: Müller HJ, Scott RJ, Webwer W (eds). Hereditary cancer. Basel: Kavger, 1995: 141-5.
24. Joenje H. Fanconi anaemia complementation groups in Germany and The Netherlands. Hum Genet 1996; 97: 280-2.
25. Joenje H, Oostra AB, van Berkel CGM, Di Summa F, Pronk JC, Arwert F. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet 1997; 61: 940-4.
26. Alter BR Fanconi anemia. Current Concepts. Am J Pediatr Hematol Oncol 1992; 14: 170-6.
27. Yamashita T, Wu N, Kupfer G, Corless C, Joenje H, Grompe M et al. Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity. Blood 1996; 87 (10): 4424-32.
28. Auerbach AD, Rogatko A, Schroeder-Kurt TM. International Fanconi Anemia Registry: Relation of clinical symptoms to diepoxibutane sensitivity. Blood 1989; 73 (2): 391-6.
29. Savoia A, Zatterale A, Del Principe D, Joenje H. Fanconi anaemia in Italy: High prevalence of complementation group A in two geographic clusters. Hum Genet 1996; 97: 599-603.
30. Daly LE, Bourke GJ, McGilvray J. Interpretation and uses of medical statistics. Oxford: Blackwell Scientific publications, 1991: 441.
31. Digweed M, Sperling K. Molecular analysis of Fanconi anemia. Bioessays 1996; 18: 5775-80.
32. Jakobs PM, Sahaayaruban P, Saito H, Reifsteck C, Olson S, Joenje H et al. Immortalization of four new Fanconi anemia fibroblast cell lines by an improved procedure. Somat Cell Mol Genet 1996; 22: 151-7.
33. Marx MP, Smith S. Significance of cellular sensitivity in a group of parents of Fanconi Anemia patients. In: Schroeder-Kurt TM, Auerbach AD, Obe G (eds). Fanconi anemia, clinical, cytogenetic and experimental aspects. Berlin Heidelberg: Springer Verlag, 1989: 425-33.
34. Kwee ML, Kuyt LP. Fanconi anemia in the Netherlans. In: Schroeder-Kurt TM, Auerbach AD, Obe G (eds). Fanconi anemia, clinical, cytogenetic and experimental aspects. Berlin Heidelberg: Springer Verlag, 1989; 219-34.
35. Alter BR Fanconi's anemia and malignancies. Am J Hematol 1996; 53: 99-110.
36. Porteous MEM, Cross Y, Burn J. VACTERL with hydrocephalus: One end of the Fanconi anemia spectrum of anomalies. Am J Med Genet 1992; 43: 1032-5.
37. Rossbach HC, Sutcliffe MJ, Haag MM, Grana NH, Rossi AR, Barbosa JL. Fanconi anemia in brothers initially diagnosed with VACTERL association with hydrocephalus, and subsequently with Baller-Gerold syndrome. Am J Med Genet 1996; 61: 65-70.
38. Altay C, Alikasifoglu M, Kara A, Tuncbilek E, Ozbek N, Schroeder-Kurt TM. Analysis of 65 Turkish patients with congenital aplastic anemia (Fanconi anemia and non-Fanconi anemia): Hacettepe experience. Clin Genet 1997; 51: 296-302.
39. Macdougall LG, Rosendorff J, Poole JE, Cohn RJ, McElligott SE. Comparative study of Fanconi anaemia in children of different ethnic origin in South Africa. Am J Med Genet 1994; 52: 279-84.
40. Lo Ten Foe J, Rooimans MA, Guille JJP, Pals G, Kruyt FAE, Pronk J et al. Somatic mosaicism in Fanconi anemia: Molecular Basis and clinical significance. Eur J Hum Genet 1997; 5: 137-43.
41. Wolf U. Identical mutations and phenotypic variation. Hum Genet 1997; 100: 305-19.